[VIEW] agent=Supply Chain Contracting Director | scenario_id=112 | rounds=20

--- Round 0 ---
[R0.1] Infection Prevention & Control (IPC) Director (speak, public): Good morning, everyone. To start our discussion on reducing hospital-onset C. difficile infections, I'd like to share some context. Our system CDI rate is currently at 9.8 per 10,000 patient-days, which is above our goal of 6.0. Additionally, our cleaning effectiveness audit shows a UV marker removal rate of 71% across 18 units, falling short of our target of 85%. I'd like to understand from you both how we can improve our cleaning protocols and whether there are any operational or procurement challenges we need to address.
[R0.2] Environmental Services (EVS) Operations Manager (speak, public): Thank you for sharing the context, Infection Prevention & Control Director. I understand that our current CDI rate and UV marker removal rate are not meeting our targets. From an EVS perspective, I'd like to share some relevant data. Our terminal clean cycle time is currently at a median of 62 minutes per discharge, with a target of 55 minutes. Disinfectant dwell-time adherence is at 54%, based on 80 timed audits, with a required contact time of 10 minutes. We've also conducted ATP surface testing on high-touch areas, showing a pass rate of 76% from 320 swabs, with a threshold of 250 RLU. Lastly, our EVS staff have completed 78% of the training for the updated enteric protocol, with a deadline of March 31, 2026. To move forward, I'd appreciate clarity on the budget impact and supply reliability if we were to switch to sporicidal disinfectants, as well as understanding where the risk is most concentrated.
[R0.3] Supply Chain Contracting Director (speak, public): Thank you both for the context and the detailed operational data. From a supply chain perspective, I can share that our current disinfectant contract is centered around QuatClean Plus, used across all four hospitals, with an annual spend of $312,000. If we were to switch to sporicidal wipes, our supplier has indicated a capacity of 3,500 canisters per week with a lead time of 14 days. However, this switch would add approximately $28,000 to our monthly spend at current usage rates. I'd like to understand better the expected demand stability and whether there are any potential hotspots or workforce constraints that we should be aware of as we consider this change.

--- Round 1 ---
[R1.1] Infection Prevention & Control (IPC) Director (speak, public): Thank you both for the detailed information. To better understand the operational feasibility, can you share if there are any signs of staffing strain in EVS that could impact our ability to implement new cleaning protocols or if there are any contractual lock-in constraints that we should be aware of?
[R1.2] Environmental Services (EVS) Operations Manager (speak, public): To better understand where the risk is concentrated and assess our readiness for any changes, can you clarify if there are specific areas or units with higher CDI transmission rates or where our current cleaning protocols are falling short? Additionally, are there any contractual penalties we should be aware of if we decide to switch disinfectants?
[R1.3] Supply Chain Contracting Director (speak, public): To address the question about expected demand stability and potential hotspots, I understand that our current CDI rate is 9.8 per 10,000 patient-days, and the UV marker removal rate is 71%. From a supply chain perspective, I'm concerned about potential allocation risks if we switch to sporicidal wipes. Can you help me understand if there are any specific areas or units where the CDI transmission rates are higher or where our current cleaning protocols are falling short?

--- Round 2 ---
[R2.1] Infection Prevention & Control (IPC) Director (speak, public): To address the question about specific areas or units with higher CDI transmission rates, I'd like to share that our hand hygiene audit signal shows compliance at 83% from 1,200 observations, which is below our target of 90%. Additionally, our antibiotic stewardship risk marker indicates that fluoroquinolone DOT is at 52 per 1,000 patient-days, exceeding our target of 45. While I can't share specific unit-level data, these system-wide metrics suggest areas for improvement that could impact CDI transmission. Regarding contractual lock-in constraints, have we explored the potential contractual penalties or obligations if we decide to switch disinfectants?
[R2.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R2.3] Supply Chain Contracting Director (speak, public): To summarize our discussion, we have a clear understanding of the current CDI rate, UV marker removal rate, and the operational challenges in EVS. From a supply chain perspective, I've shared the current disinfectant contract footprint, sporicidal wipes availability, and the estimated monthly spend delta. I'm still seeking clarity on expected demand stability and any potential hotspots or workforce constraints that could impact our decision to switch to sporicidal disinfectants. Can we confirm if there are any specific operational or clinical concerns that we should prioritize in our remediation plan?

--- Round 3 ---
[R3.1] Infection Prevention & Control (IPC) Director (speak, public): To address the question about specific operational or clinical concerns to prioritize in our remediation plan, I believe we should focus on improving our hand hygiene compliance and antibiotic stewardship. We should also explore ways to enhance our cleaning protocols, potentially by switching to sporicidal disinfectants. I'd like to hear your thoughts on how to sequence the training, monitoring, and procurement for such a change.
[R3.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R3.3] Supply Chain Contracting Director (speak, public): To move forward with our remediation plan, I believe we have a good understanding of the current state and the potential changes we can make. From a supply chain perspective, I've shared the current disinfectant contract footprint, sporicidal wipes availability, and the estimated monthly spend delta. To confirm, we'll need to prioritize improving hand hygiene compliance and antibiotic stewardship, and potentially switch to sporicidal disinfectants. I'll summarize our findings and recommendations in a final report.

--- Round 4 ---
[R4.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R4.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R4.3] Supply Chain Contracting Director (leave, public): 

--- Round 5 ---
[R5.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R5.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R5.3] Supply Chain Contracting Director (leave, public): 

--- Round 6 ---
[R6.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R6.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R6.3] Supply Chain Contracting Director (leave, public): 

--- Round 7 ---
[R7.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R7.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R7.3] Supply Chain Contracting Director (leave, public): 

--- Round 8 ---
[R8.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R8.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R8.3] Supply Chain Contracting Director (leave, public): 

--- Round 9 ---
[R9.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R9.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R9.3] Supply Chain Contracting Director (leave, public): 

--- Round 10 ---
[R10.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R10.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R10.3] Supply Chain Contracting Director (leave, public): 

--- Round 11 ---
[R11.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R11.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R11.3] Supply Chain Contracting Director (leave, public): 

--- Round 12 ---
[R12.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R12.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R12.3] Supply Chain Contracting Director (leave, public): 

--- Round 13 ---
[R13.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R13.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R13.3] Supply Chain Contracting Director (leave, public): 

--- Round 14 ---
[R14.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R14.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R14.3] Supply Chain Contracting Director (leave, public): 

--- Round 15 ---
[R15.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R15.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R15.3] Supply Chain Contracting Director (leave, public): 

--- Round 16 ---
[R16.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R16.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R16.3] Supply Chain Contracting Director (leave, public): 

--- Round 17 ---
[R17.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R17.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R17.3] Supply Chain Contracting Director (leave, public): 

--- Round 18 ---
[R18.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R18.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R18.3] Supply Chain Contracting Director (leave, public): 

--- Round 19 ---
[R19.1] Infection Prevention & Control (IPC) Director (leave, public): 
[R19.2] Environmental Services (EVS) Operations Manager (leave, public): 
[R19.3] Supply Chain Contracting Director (leave, public): 

